KKR Genetic Disorder L.P. - May 12, 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
10%+ Owner
Signature
See Exhibit 99.1
Stock symbol
BBIO
Transactions as of
May 12, 2025
Transactions value $
-$205,200,000
Form type
4
Date filed
5/14/2025, 05:24 PM
Previous filing
Mar 7, 2025
SEC
View on sec.gov

Reporting Owners (9)

Name Relationship Address Signature Signature date CIK
KKR Genetic Disorder L.P. 10%+ Owner 30 HUDSON YARDS, NEW YORK See Exhibit 99.1 2025-05-14 0001780408
KKR Genetic Disorder GP LLC 10%+ Owner 30 HUDSON YARDS, NEW YORK See Exhibit 99.1 2025-05-14 0001780428
KKR Group Partnership L.P. 10%+ Owner 30 HUDSON YARDS, NEW YORK See Exhibit 99.1 2025-05-14 0001472698
KKR Group Holdings Corp. 10%+ Owner 30 HUDSON YARDS, NEW YORK See Exhibit 99.1 2025-05-14 0001743754
KKR Group Co. Inc. 10%+ Owner 30 HUDSON YARDS, NEW YORK See Exhibit 99.1 2025-05-14 0001932162
KKR & Co. Inc. 10%+ Owner 30 HUDSON YARDS, NEW YORK See Exhibit 99.1 2025-05-14 0001404912
KKR Management LLP 10%+ Owner 30 HUDSON YARDS, NEW YORK See Exhibit 99.1 2025-05-14 0001472694
KRAVIS HENRY R 10%+ Owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK See Exhibit 99.1 2025-05-14 0001081714
ROBERTS GEORGE R 10%+ Owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK See Exhibit 99.1 2025-05-14 0001081715

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Sale -$205M -6M -31.15% $34.20 13.3M May 12, 2025 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

KKR Genetic Disorder L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Reflects the sale of 6,000,000 shares of common stock of BridgeBio Pharma, Inc. (the "Issuer"), par value $0.001 per share (the "Common Stock"), by KKR Genetic Disorder L.P. in a block sale at a price per share of $34.20 pursuant to Rule 144 of the Securities Act of 1933, as amended.
F2 The shares of Common Stock are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC is the general partner of KKR Genetic Disorder L.P. KKR Group Partnership L.P. is the sole member of KKR Genetic Disorder GP LLC. KKR Group Holdings Corp. is the general partner of KKR Group Partnership L.P. KKR Group Co. Inc. is the sole shareholder of KKR Group Holdings Corp. KKR & Co. Inc. is the sole shareholder of KKR Group Co. Inc. KKR Management LLP is the Series I preferred stockholder of KKR & Co. Inc. Messrs. Henry R. Kravis and George R. Roberts are the founding partners of KKR Management LLP but disclaim beneficial ownership of the reported securities.
F3 Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein.